DOJ Backs AbbVie in 340B Drug Pricing Dispute with Colorado

The U.S. Department of Justice (DOJ) is supporting AbbVie Inc. In its legal challenge against a Colorado law restricting drug discounts under the 340B Drug Pricing Program. This move signals a significant federal stance on the ongoing debate surrounding the program’s implementation and potential for abuse.

Understanding the 340B Program

Created over three decades ago, the 340B program was established to provide discounted drugs to hospitals and clinics serving a disproportionate number of low-income and rural patients [1]. Participating drug manufacturers offer substantial discounts – typically ranging from 25% to 50%, and sometimes higher – in exchange for continued participation in Medicare and Medicaid [1].

The Dispute Over Contract Pharmacies

Around six years ago, many pharmaceutical companies began limiting 340B discounts when hospitals and clinics utilized contract pharmacies. Instead of dispensing medications directly to patients, these facilities began partnering with external pharmacies for delivery or patient pickup [1]. Pharmaceutical companies argue this practice created opportunities for abuse, including duplicate billings, product diversion, and improper rebates [1].

Colorado’s Response and AbbVie’s Challenge

Colorado responded by enacting a law prohibiting pharmaceutical companies from restricting access to 340B discounts based on the pharmacy used by the patient [1]. AbbVie subsequently filed a lawsuit challenging the constitutionality of this law, arguing that it interferes with the federal 340B program [2].

DOJ’s Amicus Brief

The DOJ has filed an amicus brief supporting AbbVie’s position, arguing that federal law preempts Colorado’s 340B Contract Pharmacy Protection Act [2]. The DOJ contends that the federal government has a strong interest in the smooth functioning of the drug discount program [2], and that Colorado’s law undermines this function [1].

Implications of the DOJ’s Support

The DOJ’s backing of AbbVie signals a potential shift in the federal government’s approach to the 340B program. It suggests a willingness to defend pharmaceutical companies’ rights to manage their participation in the program and to prevent what they perceive as abuse. The outcome of this case could have significant implications for other states considering similar legislation and for the future of the 340B program as a whole [1].

About the 340B Program

The 340B Drug Pricing Program is administered by the Health Resources and Services Administration (HRSA), a division of the U.S. Department of Health and Human Services [4]. Congress has periodically modified the program, expanding eligibility and increasing HRSA’s enforcement powers [4].